Peptide And Oligonucleotide CDMO Market Size and Share

Peptide And Oligonucleotide CDMO Market Analysis by Mordor Intelligence
The Peptide and Oligonucleotide CDMO market is valued at USD 2.68 billion in 2025 and is forecast to reach USD 4.66 billion by 2030, registering an 11.7% CAGR over the period. Supply-demand imbalance, highlighted by ongoing shortages in GLP-1 receptor agonists and siRNA therapeutics, has repositioned contract development and manufacturing organizations (CDMOs) from niche partners to critical nodes in the pharmaceutical value chain. Capital-intensive expansions such as CordenPharma’s EUR 900 million (USD 1.05 billion) upgrade in Switzerland signal an industry scrambling to alleviate capacity bottlenecks while simultaneously navigating sustainability pressures from solvent-intensive peptide synthesis. Regionally, North America remains the revenue anchor, yet Asia Pacific’s low-cost manufacturing base and aggressive buildouts by WuXi STA and Samsung Biologics are redrawing competitive maps. Product complexity is rising as multimodal, peptide-oligonucleotide conjugates move from research to clinic, demanding new analytical expertise and pushing CDMOs toward end-to-end service models that include process development, fill-finish, and regulatory support.
Key Report Takeaways
- By product, peptide CDMO services led with a 55.6% revenue share in 2024, while peptide-oligonucleotide conjugate services are projected to expand at a 16.5% CAGR to 2030.
- By application, therapeutics held 72.1% of the Peptide And Oligonucleotide CDMO market share in 2024; gene-editing applications record the highest forecast CAGR at 15.2% through 2030.
- By service type, GMP manufacturing commanded 61.5% of the Peptide and Oligonucleotide CDMO market size in 2024, whereas fill-finish and packaging are advancing at a 14.6% CAGR to 2030.
- By end user, pharmaceutical and biotechnology companies accounted for a 68.3% revenue share in 2024; gene and cell therapy developers are growing at a 14.3% CAGR through 2030.
- By geography, North America retained 38.8% of the market share in 2024, while Asia Pacific is the fastest-growing region, with a 13.4% CAGR through 2030.
Global Peptide And Oligonucleotide CDMO Market Trends and Insights
Drivers Impact Analysis
Driver | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
---|---|---|---|
Surging GLP-1 & siRNA clinical pipeline is straining global GMP capacity | +3.20% | Global (acute in North America & Europe) | Short term (≤ 2 years) |
Growing demand for peptide-/ASO-enabled precision medicines | +2.80% | Global (early adoption in North America & EU) | Medium term (2-4 years) |
Shift toward outsourcing by big pharma & VC-backed biotechs | +2.10% | Global (focus in North America & APAC) | Medium term (2-4 years) |
Continuous-flow synthesis platforms slash COGS & waste | +1.90% | Global (early use in Europe & North America) | Long term (≥ 4 years) |
Near-term launch of self-administered oral peptides boosts CDMO volumes | +1.40% | Global (initial focus in North America & EU) | Short term (≤ 2 years) |
AI-driven sequence optimization accelerates candidate turnover | +1.10% | Global (leadership in North America & APAC) | Long term (≥ 4 years) |
Source: Mordor Intelligence
Surging GLP-1 & siRNA Clinical Pipeline Is Straining Global GMP Capacity
Demand for GLP-1 receptor agonists and siRNA drugs is outpacing available GMP suites, giving CDMOs unprecedented pricing power as pharmaceutical sponsors scramble for multi-year capacity guarantees. Novo Nordisk’s 2024 shortages of Ozempic and Wegovy underscored systemic constraints, prompting bilateral supply-risk mitigation strategies that hinge on dual-sourcing contracts. CordenPharma’s EUR 900 million (USD 1.05 billion) Swiss build-out is tailored to complex GLP-1 analogs, while a handful of specialized CDMOs dominate commercial-scale siRNA purification. Contract durations are lengthened and include take-or-pay clauses that lock in volumes years before anticipated market approval, reshaping drug-development capital planning.
Growing Demand for Peptide-/ASO-Enabled Precision Medicines
Therapeutic pipelines now routinely combine peptide carriers with antisense oligonucleotides to boost cellular uptake, transforming manufacturing into a hybrid chemistry-plus-biologics discipline. The US FDA’s 2024 draft guidance on oligonucleotide therapeutics amplified the need for advanced impurity profiling, driving CDMOs to install next-generation mass-spectrometry and capillary electrophoresis platforms.[1]FDA, “Draft Guidance: Oligonucleotide Therapeutics Development,” fda.gov Collaborative programs such as Secarna and Orbit Discovery’s peptide-conjugated ASOs illustrate sponsors’ preference for partners that master overlapping chemistries.[2]Nature Biotechnology editors, “Secarna and Orbit Discovery Launch Peptide-Conjugated ASO Program,” nature.com In turn, CDMOs capable of cross-modal analytics gain defensible moats and command premium development fees.
Shift Toward Outsourcing by Big Pharma & VC-Backed Biotech’s
Rising R&D costs and board-level mandates for capital efficiency are steering large pharma and venture-funded biotech toward asset-light operating models. Thermo Fisher’s multi-year, USD 40–50 billion M&A budget and Novo Holdings’ USD 16.5 billion Catalent buyout reflect vertical-integration plays that secure pipeline capacity while retaining external revenue streams. This outsourcing wave is also reconfiguring risk sharing: milestone-linked manufacturing agreements now embed co-development options, creating mutual incentive structures that align CDMO productivity with sponsor speed-to-market objectives.
Continuous-Flow Synthesis Platforms Slash COGS & Waste
Continuous-flow peptide synthesis cuts solvent consumption by up to 80% versus batch SPPS, directly answering emerging ESG mandates. Early adopters like Eli Lilly report tighter critical quality attribute (CQA) distributions and lower cost of goods—outcomes that resonate with payers seeking cost containment. Regulatory conservatism is easing as agencies publish guidance on real-time release in continuous systems, rewarding pioneering CDMOs with first-mover advantages and differentiated carbon footprint disclosures for sustainability-minded clients.
Restraints Impact Analysis
Restraint | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
---|---|---|---|
Chronic talent shortage in large-scale downstream purification | -2.30% | Global (acute in North America & Europe) | Medium term (2-4 years) |
Regulatory harmonisation lags for hybrid peptide-oligo conjugates | -1.80% | Global (FDA vs EMA divergence) | Long term (≥ 4 years) |
Global solvent-recycling mandates add capex pressure | -1.20% | Europe-led; spillover to North America & APAC | Medium term (2-4 years) |
Limited supply of protected nucleoside phosphoramidites | -0.90% | Global (supply concentrated in Europe & North America) | Short term (≤ 2 years) |
Source: Mordor Intelligence
Chronic Talent Shortage in Large-Scale Downstream Purification
Staffing gaps for purification scientists delay facility ramps, forcing CDMOs to run sub-optimal batch scheduling and reject incremental business. Tight labor markets have doubled the average recruitment lead times for senior chromatographers, inflating project timelines and driving salary inflation well above market averages. Workforce development partnerships with universities and targeted retraining programs are emerging, but it will take several years to ease the supply-demand mismatch.
Regulatory Harmonization Lags For Hybrid Peptide-Oligo Conjugates
Divergent FDA and EMA review frameworks create duplicative data packages for peptide-oligonucleotide conjugates, adding uncertainty to CMC planning.[3]EMA, “Reflection Paper on Synthetic Peptide APIs,” ema.europa.eu CDMOs must design flexible processes that can toggle between agency expectations on sequence-related impurities and conjugation site validation, raising up-front development costs and extending submission timelines.
Segment Analysis
By Product: Peptide Dominance Faces Conjugate Disruption
Peptide CDMO services generated 55.6% revenue in 2024, reflecting mature infrastructure and validated regulatory pathways. Oligonucleotide contracts occupy a growing midpoint, but the fastest-rising opportunity lies in peptide-oligonucleotide conjugate manufacturing, forecast at a 16.5% CAGR. The Peptide and Oligonucleotide CDMO market size for conjugate services is projected to widen sharply as sponsors chase multimodal delivery advantages tied to precision medicine. Leaders such as Bachem leverage half-century know-how, while newer entrants carve niches by linking state-of-the-art solid-phase peptide synthesis with high-throughput oligo chemistry suites.
Manufacturing convergence creates high technical hurdles. Processes must reconcile divergent solvent systems, deprotection chemistries, and analytical release criteria. Few facilities can manage in-line conjugation at scale, making capacity scarce and margins attractive. CDMOs with frontline regulatory dialogue and dual-competency staff win early-stage programs that later convert into long-term commercial contracts, reinforcing a virtuous capacity-utilization cycle.

Note: Segment shares of all individual segments available upon report purchase
By Application: Therapeutics Leadership Yields to Gene Editing Growth
Therapeutics contracts delivered 72.1% of 2024 revenue, buoyed by chronic disease indications that require sustained supply volumes. Yet the Peptide And Oligonucleotide CDMO market is pivoting swiftly: gene-editing applications will outpace all others at a 15.2% CAGR through 2030, underpinned by CRISPR-Cas9 pipelines needing guide RNA and peptide-based delivery vectors. The resulting diversification reduces reliance on traditional metabolic disease franchises and stabilizes the project mix across therapeutic areas.
Emerging indications drive specialized analytical validation such as off-target editing assays—that further entrench CDMOs able to integrate multidisciplinary QC workflows. Sponsors reward such breadth with multi-year master service agreements, insulating preferred partners from commoditization pressures and price erosion that historically plagued mature therapeutics supply categories.
By Service Type: GMP Manufacturing Dominance Challenged by Fill-Finish Growth
GMP manufacturing supplied 61.5% of segment revenue in 2024, cementing its role as the Peptide and Oligonucleotide CDMO market’s economic bedrock. However, fill-finish and packaging are the fastest-growing offerings at 14.6% CAGR, reflecting downstream constraints that now bottleneck launch schedules. Integrated providers that couple synthesis with specialized aseptic vialing or autoinjector filling offer one-stop solutions attractive to lean biotech teams.
This evolution elevates capital expenditure on isolator technology, lyophilization suites, and cold-chain infrastructure, but also strengthens customer lock-in by embedding CDMOs deep into the final-product value stream. The Peptide And Oligonucleotide CDMO market share commanded by pure-play development shops is expected to erode as full-service peers capture lifecycle value from IND through commercial supply.

Note: Segment shares of all individual segments available upon report purchase
By End User: Pharma Dominance Faces Gene Therapy Disruption
Pharmaceutical and biotechnology enterprises retained 68.3% of 2024 contract value due to blockbuster GLP-1 scale-ups. Yet the fastest expansion comes from gene and cell therapy developers, projected at 14.3% CAGR. These ventures require bespoke oligonucleotide payloads, high-purity peptides for delivery, and regulatory documentation tuned for autologous workflows, all of which push CDMOs to customize batch sizes and qualification protocols.
Sponsors value partners that can flex between gram-scale research lots and multi-kilogram commercial campaigns without tech transfer delays. Consequently, CDMOs investing in modular cleanrooms and single-use equipment gain agility advantages that resonate with venture-backed clients operating on milestone-driven financing.
By Scale: Commercial Services Lead Despite Clinical Growth
Commercial-scale work captured 52.7% of the 2024 turnover, underscoring long-duration, high-volume supply agreements for marketed peptides and oligonucleotides. Yet early-phase clinical support will outstrip all other scales at a 13.9% CAGR to 2030, propelled by venture-capital funding cycles that prize quick proof-of-concept data. The Peptide And Oligonucleotide CDMO market size tied to phase I–II projects is poised to expand in parallel with record biotech IPO pipelines.
Early-stage contracts often feature higher per-gram margins, but they also demand rapid tech transfer and flexible scheduling. CDMOs that master phase-appropriate validation and can rapidly pivot suites between client projects will capture a disproportionate share of this high-growth revenue pool.
Geography Analysis
North America’s 38.8% share in 2024 reflects entrenched pharma ecosystems, FDA familiarity, and a network of multi-modal innovation hubs. Recent multiyear capacity commitments from Thermo Fisher exemplify how proximity and regulatory competence offset higher operating costs. Yet scaling challenges persist: energy prices, solvent-disposal regulations, and skilled-labor shortages escalate the total cost of ownership, prompting sponsors to reassess regional sourcing strategies in favor of blended North America–Asia portfolios.
Asia Pacific is rewriting competitive baselines. Samsung Biologics’ fifth plant and WuXi STA’s Taixing peptide campus illustrate a surge of capital exceeding USD 2 billion across South Korea and China alone. Lower unit costs, government incentives, and increasingly FDA-audited facilities are eroding historical perceptions of quality gaps. As patent cliffs squeeze pricing on chronic-disease therapeutics, these economics will pull a larger slice of volume production eastward, even as complex early development work remains in the West.
Europe leverages deep regulatory integration and a concentration of legacy peptide expertise to protect share in high-value, low-volume projects. Switzerland’s dual anchors—Bachem and CordenPharma—serve as cluster magnets, attracting ancillary suppliers and academic collaborations that reinforce regional dominance in ultra-high-purity synthesis. However, environmental legislation that tightens solvent-emission caps is accelerating capex requirements, compelling European CDMOs to adopt continuous-flow technologies sooner than peers elsewhere.

Competitive Landscape
Competition is moderate and revolves around capacity access rather than price. Incumbents such as Bachem, PolyPeptide Group, and Thermo Fisher preserve leadership via multi-decade regulatory track records, proprietary process know-how, and strategic geographic footprints. Seller-market dynamics prevail: clients routinely accept volume-reservation premiums to guarantee launch timelines. Asian peers—Samsung Biologics, WuXi STA and SK pharmteco—are expanding aggressively, leveraging cost economics and scale to win commercial batch contracts, pressuring Western CDMOs to emphasize technology leadership and service breadth.
Strategic differentiation is shifting from single-service proficiency to end-to-end offerings. Lonza, Catalent (post-Novo Holdings) and Samsung Biologics now pitch cradle-to-commercial packages spanning cell-line development, conjugation, fill-finish and serialization. Technology races center on continuous-flow reactors, AI-driven sequence design and solvent-recycling platforms that cut cost of goods while meeting tightening ESG standards. White-space opportunities persist in conjugate GMP suites and cold-chain fill-finish capacity—areas where demand outstrips supply and entry barriers remain high.
M&A momentum continues as scale and integrated capabilities become prerequisites for preferred-supplier status. Mega-deals (e.g., Catalent, BIOVECTRA) and focused tuck-ins (e.g., PCI’s fill-finish acquisitions) signal a consolidation cycle that will reshape vendor lists over the next five years, likely boosting the Peptide and Oligonucleotide CDMO market’s average contract value and increasing switching costs for sponsors.
Peptide And Oligonucleotide CDMO Industry Leaders
-
Thermo Fisher Scientific Inc.
-
Polypeptide Group
-
Wuxi Apptec Co., Ltd.
-
Genscript Biotech Corporation
-
CordenPharma International
- *Disclaimer: Major Players sorted in no particular order

Recent Industry Developments
- April 2025: Samsung Biologics began operations at Plant 5, adding 180,000 L capacity and opening a dedicated ADC facility, alongside a USD 1.4 billion CDMO contract with a European pharma company.
- March 2025: Merck KGaA reported 2024 Life Science Services revenue of EUR 722 million (USD 850 million) and unveiled investments in ADC and bioprocessing capacity.
- January 2025: Samsung Biologics signed a USD 1.4 billion manufacturing agreement with a European client at the Songdo campus, which will extend through 2030.
- December 2024: Novo Holdings finalized its USD 16.5 billion acquisition of Catalent, creating vertically integrated peptide and oligonucleotide supply solutions.
Global Peptide And Oligonucleotide CDMO Market Report Scope
As per the report's scope, peptides are short chains of amino acids, and oligonucleotides are short DNA or RNA molecules. In biotechnology and drug development, peptide oligonucleotides are used for various purposes, including gene therapy and diagnostics. CDMOs offer expertise in synthesis, purification, and other processes involved in manufacturing these molecules.
The peptide and oligonucleotide CDMO market is segmented by product, application, end user, and geography. The market is segmented by products, such as peptide CDMO and oligonucleotide CDMO. The market is segmented by application into therapeutics, research applications, diagnostics, and other applications. End user segments the market as pharmaceutical and biotechnology companies, research institutes, contract research organizations (CROs), and academic and government organizations. The market is segmented by geography (North America, Europe, Asia-Pacific, the Middle East and Africa, and South America). The report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD) for the above segments.
By Product | Peptide CDMO | ||
Oligonucleotide CDMO | |||
Peptide-Oligonucleotide Conjugate CDMO | |||
By Application | Therapeutics | ||
Diagnostics | |||
Research & Discovery | |||
Vaccines | |||
Gene Editing | |||
By Service Type | Process Development | ||
GMP Manufacturing | |||
Analytical & Quality Control | |||
Fill-Finish & Packaging | |||
Regulatory & CMC Support | |||
By End User | Pharmaceutical & Biotechnology Companies | ||
Academic & Research Institutes | |||
Diagnostic Companies | |||
Gene- & Cell-Therapy Developers | |||
Others | |||
By Geography | North America | United States | |
Canada | |||
Mexico | |||
Europe | Germany | ||
United Kingdom | |||
France | |||
Italy | |||
Spain | |||
Rest of Europe | |||
Asia Pacific | China | ||
Japan | |||
India | |||
South Korea | |||
Australia | |||
Rest of Asia Pacific | |||
Middle East & Africa | GCC | ||
South Africa | |||
Rest of Middle East & Africa | |||
South America | Brazil | ||
Argentina | |||
Rest of South America |
Peptide CDMO |
Oligonucleotide CDMO |
Peptide-Oligonucleotide Conjugate CDMO |
Therapeutics |
Diagnostics |
Research & Discovery |
Vaccines |
Gene Editing |
Process Development |
GMP Manufacturing |
Analytical & Quality Control |
Fill-Finish & Packaging |
Regulatory & CMC Support |
Pharmaceutical & Biotechnology Companies |
Academic & Research Institutes |
Diagnostic Companies |
Gene- & Cell-Therapy Developers |
Others |
North America | United States |
Canada | |
Mexico | |
Europe | Germany |
United Kingdom | |
France | |
Italy | |
Spain | |
Rest of Europe | |
Asia Pacific | China |
Japan | |
India | |
South Korea | |
Australia | |
Rest of Asia Pacific | |
Middle East & Africa | GCC |
South Africa | |
Rest of Middle East & Africa | |
South America | Brazil |
Argentina | |
Rest of South America |
Key Questions Answered in the Report
What is the current size of the Peptide and Oligonucleotide CDMO market?
The Peptide and Oligonucleotide CDMO market is valued at USD 2.68 billion in 2025 and is projected to grow to USD 4.66 billion by 2030.
Which region is growing fastest for peptide and oligonucleotide outsourcing?
Asia Pacific registers the highest growth, with a 13.4% CAGR through 2030, driven by large-scale capacity additions and cost advantages.
Why are peptide-oligonucleotide conjugates gaining traction?
Conjugates combine peptide targeting with oligonucleotide therapeutic payloads, improving delivery efficiency and creating high-margin manufacturing demand that few CDMOs can meet.
What service segment is expanding quickest within CDMOs?
Fill-finish & packaging services are growing at a 14.6% CAGR as bottlenecks shift downstream and sponsors seek integrated end-to-end suppliers.
How are CDMOs addressing sustainability concerns in peptide synthesis?
Early adopters are rolling out continuous-flow manufacturing, which reduces solvent use by up to 80% and lowers carbon footprints, aligning with emerging ESG mandates.
Page last updated on: July 6, 2025